Zynerba Pharmaceuticals Announces Clinical Development Updates For FXS, ASD, 22q And DEE; Plans To Focus Development Of Zygel In FXS, ASD And 22q, Plans To Initiate Phase 3 Trial With Zygel In ASD In 2H 2022